Protozoal Infections

Miltefosine Gains Orphan Drug Status for Serious CNS Infections

By June 28, 2017

Miltefosine is an alkyllysophospholipid analogue drug with in vitro activity against the promastigote and amastigote stages of Leishmania species. It is already approved to treat visceral, mucosal and cutaneous leishmaniasis in patients aged ≥12 years; it is the first oral treatment for this rare tropical parasitic disease.

Newer Treatments Critical to Fight 'Silent Killer' Disease in U.S.

April 20, 2017

"Less than 1% with the infection are receiving treatment for Chagas disease," said Dr. Sheba Meymandi, Director of the Center of Excellence for Chagas Disease at Olive View-UCLA Medical Center.

Impavido Designated Orphan Drug for Amebic Meningoencephalitis

December 16, 2016

Profounda announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation for Impavido (miltefosine) to treat primary amebic meningoencephalitis (PAM), also known as the "Brain Eating Amoeba".

Impavido Available for Rare Parasitic Disease

By March 22, 2016

Profounda announced the launch of Impavido (miltefosine) for the treatment of visceral, mucosal, and cutaneous leishmaniasis in patients aged ≥12 years.

Daraprim Alternative Announced in Response to Price Hike

By October 23, 2015

Imprimis Pharmaceuticals announced that it has made available a compounded formulation of pyrimethamine and leucovorin as a lower-cost alternative to Daraprim (pyrimethamine; Turing Pharmaceuticals).

Criticism Sparks Cost Reduction in Toxoplasmosis Pill

By September 23, 2015

Turing Pharmaceuticals has agreed to reduce the cost of its drug Daraprim (pyrimethamine) after receiving significant criticism due to a sudden increase in the price of the medication.

Benznidazole Tx Explored in Chagas' Cardiomyopathy

September 01, 2015

For patients with established Chagas' cardiomyopathy, benznidazole may reduce serum parasite detection.

When Cortricosteroid Use Can Be Life-Threatening for an Asthma Patient

By July 08, 2015

Clinicians should exercise caution when prescribing steroids in patients presenting with an exacerbation of asthma in areas endemic for Strongyloides stercoralis (SS), as a patient experienced hyperinfection syndrome from prednisone treatment at the time of SS infection.

"Kissing Bugs" Spreading Chagas Disease in U.S.

November 05, 2014

Residents of the southern United States may be at risk for Chagas disease, which can lead to severe heart disease and death.

New Government Policies on Pathogen Research Issued, But Will They Be Effective?

September 25, 2014

New policy guidelines issued by the White House Office of Science and Technology Policy are calling for U.S. universities to carefully monitor their life sciences research on dangerous pathogens and toxins for both benefits and risks.

Guidance on STI Screening for Teens Issued by AAP

July 03, 2014

Guidance is provided for screening adolescents and young adults for sexually transmitted infections (STIs) in an American Association of Pediatrics (AAP) Policy Statement.

Posaconazole Found Lacking in Treatment of Chagas' Disease

May 16, 2014

Compared to the standard of care (benznidazole), the new drug posaconazole is not effective for the treatment of Chagas' disease.

Parasitic Infections More Common in U.S. Than Estimated

May 09, 2014

The Centers for Disease Control (CDC) has targeted 5 neglected parasitic infections (NPIs) in the United States as priorities for public health action.

FDA Approves First Cutaneous, Mucosal Leishmaniasis Drug

March 20, 2014

The FDA has approved Impavido (miltefosine; Paladin Therapeutics) for the treatment of three main types of leishmaniasis: visceral, cutaneous, and mucosal leishmaniasis in patients ≥12 years of age.

<i>E. cuniculi</i> Can Cause Febrile Illness After Transplant

February 19, 2014

Solid organ transplant recipients who become febrile weeks after transplantation may have acquired microsporidiosis from Encephalitozoon cuniculi.

CDC Ups Miltefosine Access for Free-Living Amebae Infections

August 26, 2013

The investigational drug miltefosine is now available from the CDC for patients with infections caused by free-living amebae (FLA).

Cyclosporiasis Outbreak: 400 Cases and Counting

July 29, 2013

As of August 1, 2013, the CDC has been notified of 400 cases of Cyclospora infection from 15 health departments.

CDC: U.S. Patients Suffering Tropical Infection

July 26, 2013

Cases of the intestinal infection, cyclosporiasis have caught the U.S. Centers of Disease Control and Prevention's attention when in June individuals who had not been traveling internationally at the time were infected.

Tapeworm Infections Rise in U.S.; Treatment Guidelines Issued

April 09, 2013

Adults and children with intraparenchymal neurocysticercosis, a tapeworm infection causing seizures most commonly in developing countries of Africa, Asia, and Latin America, should be treated with albendazole plus either dexamethasone or prednisolone.

xTAG Gastrointestinal Pathogen Panel Now Available

January 15, 2013

Luminex announced that it has received FDA clearance for its xTAG Gastrointestinal Pathogen Panel (GPP), a comprehensive molecular diagnostic assay that tests for >90% of bacterial, viral, and parasitic causes of infectious gastroenteritis in a single assay.

Neti Pots Linked to Deaths From Amebic Infection

August 24, 2012

Two patients who died of an amebic infection had no history of freshwater exposure but had ameba in their household plumbing and used a nasal irrigation device for sinus problems.

Self-Directed Violence, Suicide Up in Parasite-Infected Women

July 06, 2012

Women infected with the common parasite Toxoplasma gondii (T. gondii) have an increased risk of self-directed violence, violent suicide attempts, and suicide.

Infection Rates Unaffected by Time to Debridement of Open Fx

July 03, 2012

There is no association between infection rates and time to operative debridement of open fractures.

Claris Lifesciences' intravenous medications recalled

June 01, 2010

The FDA has notified healthcare professionals not to use the intravenous medications, metronidazole, ciprofloxacin and ondansetron manufactured by Claris Lifesciences due to contamination.